ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Lipids"

  • Abstract Number: 115 • 2015 ACR/ARHP Annual Meeting

    Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening

    Michael Grasso1, Dana Direnzo2, Yelena Yesha3, Naphtali Rishe4 and Amanda Niskar5, 1Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, 2Internal Medicine, University of Maryland Medical Center, Baltimore, MD, 3Computer Science and Electrical Engineering, Professor, Baltimore, MD, 4Computer Science, Florida International University, Miami, FL, 51330 West Peachtree Street NW, Arthritis Foundation, Atlanta, GA

    Background/Purpose: We extracted a large cohort of rheumatoid arthritis (RA) patients, on which we plan to apply big data analytics for earlier diagnosis of RA.…
  • Abstract Number: 1440 • 2014 ACR/ARHP Annual Meeting

    Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function

    Silvia Rollefstad1, Bente Halvorsen2, Tonje Skarpengland2, Sella Provan3, Tore K. Kvien4 and Anne Grete Semb1, 1Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4PsAID taskforce, EULAR, Zurich, Switzerland

    Background/Purpose  Reverse cholesterol transport (RCT) is a major anti atherogenic function of high density lipoprotein cholesterol (HDL) and has been shown to be related to…
  • Abstract Number: 1361 • 2014 ACR/ARHP Annual Meeting

    Rheumatologists’ Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center

    Ashwini Komarla1 and Alexis Ogdie2, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cardiovascular (CV) disease is a major cause of morbidity and mortality in the rheumatoid arthritis (RA) population. Thus, the recognition and management of cardiovascular…
  • Abstract Number: 1274 • 2014 ACR/ARHP Annual Meeting

    Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway

    Silvia Rollefstad1, Ingvild Eeg2, Ida K. Haugen2, Inge C. Olsen3, Nina Østerås4, Barbara Christensen2, Hilde Berner Hammer5, Lars Nordsletten6, Bård Natvig7, Tore K. Kvien8 and Anne Grete Semb1, 1Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Department of rheumatology, National Advisory Unit for rehabilitation in rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, 6Dept of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway, 7General Practice, Oslo University, Oslo, Norway, 8Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose Controversies exist regarding whether patients with osteoarthritis (OA) have an increased risk of cardiovascular (CV) disease. Our aim was to evaluate the CV risk…
  • Abstract Number: 1123 • 2014 ACR/ARHP Annual Meeting

    Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis

    Shinji Yoshida1, Katsunori Ikari1, Koichiro Yano1, Yoshiaki Toyama2, Atsuo Taniguchi3, Hisashi Yamanaka1 and Shigeki Momohara3, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose Patients with rheumatoid arthritis (RA) have a higher prevalence of dyslipidemia than healthy individuals. Since RA is a chronic inflammatory disease, an inflammatory response…
  • Abstract Number: 1063 • 2014 ACR/ARHP Annual Meeting

    Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting

    Kashif Jafri1, Lynne Taylor2, Nehal N. Mehta3, Melissa Nezamzadeh4, Joshua Baker5 and Alexis Ogdie6, 1Department of Medicine, University of Pennsylvania, Philadelphia, PA, 2Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 3Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA, 5Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 6Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Rheumatoid arthritis has been associated with an increased risk of cardiovascular morbidity and mortality.  It is unclear, however, whether this knowledge has translated into…
  • Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting

    Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months

    C. Charles-Schoeman1, A. Dikranian2, J. Taylor3, B. Wilkinson4, T. Jones5, K. Kwok6 and C. Nduaka4, 1University of California, Los Angeles, CA, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Anderson Arthritis and Rheumatology Center, Meridian, MS, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
  • Abstract Number: 2465 • 2014 ACR/ARHP Annual Meeting

    Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α

    Ikuko Masuda1,2, Kodo Okada3, Hisashi Yamanaka4 and Shigeki Momohara4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Rheumatology, Jyujyo Takeda Rehabilitation Hospital, Kyoto, Japan, 3SANSHO, Co. Ltd., Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including i) antiproliferative effect on…
  • Abstract Number: 2305 • 2014 ACR/ARHP Annual Meeting

    Improving Screening for Hyperlipidemia in Patients with Rheumatoid Arthritis at an Academic Rheumatology Practice

    Ashwini Komarla1 and Alexis Ogdie2, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose Cardiovascular disease is the leading cause of mortality in the rheumatoid arthritis (RA) population. However, cardiovascular risk factors such as hyperlipidemia are undertreated in…
  • Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting

    Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function

    Torkell Ellingsen1,2,3, Henriette Jørgensen4, Dino Demirovic4, Lone Deibjerg5, Frank Andersen5, Agnete Hedemann-Andersen5, Brian Bridal Løgstrup5,6 and Suresh Rattan4, 1Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark, 2The Danish National Registry DANBIO, Odense, Denmark, 3Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, 4Laboratory of Cellular Ageing, Institute of Molecular Biology and Genetics, Århus University, Århus, Denmark, 5Diagnostic Centre Region, Hospital Silkeborg Denmark, Silkeborg, Denmark, 6Cardiology, Skejby Hospital, Århus Universityhosital, Århus, Denmark

    Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``.  Methods: We investigated cell…
  • Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting

    Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients

    Dimitrios A. Pappas1, Ani John2, Jeffrey R. Curtis3, George W. Reed4, Jeffrey D. Greenberg5, Ashwini Shewade2, Daniel H. Solomon6, Joel M. Kremer7 and Tanya Sommers4, 1Columbia University, New York, NY, 2Genentech Inc., South San Francisco, CA, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4CORRONA, Inc., Southborough, MA, 5Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, 6Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 7Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
  • Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting

    Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib

    W. F. C. Rigby1, L. Takiya2, S. P. Wood3, H. Fan2 and T. V. Jones2, 1Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Pfizer Inc, Collegeville, PA, 3Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
  • Abstract Number: 2309 • 2013 ACR/ARHP Annual Meeting

    Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients

    Katherine P. Liao1, Jonathan Brown2, Jonathan S. Coblyn3, Paul Cohen2, Jorge Plutzky2 and Daniel H. Solomon4, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Cardiology, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA

    Background/Purpose: Cardiovascular (CV) risk is higher among rheumatic disease patients than the general population.  However, CV risk management guidelines calibrated for the rheumatic disease population…
  • Abstract Number: 1280 • 2013 ACR/ARHP Annual Meeting

    The Role of Sphingosine-1-Phosphate Receptor 3 Signaling in Murine Collagen-Induced Arthiritis

    Hidetake Nagahara1, Masataka Kohno1, Ken Murakami1, Aihiro Yamamoto1, Takahiro Seno1, Wataru Fujii1, Kazuki Fujioka1, Yuji Kukida1, Ryo Oda2, Hiroyoshi Fujiwara2 and Yutaka Kawahito1, 1Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, kyoto, Japan

    Background/Purpose: Sphingolipids represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Through the interaction with a family of five G-protein-coupled…
  • Abstract Number: 1166 • 2013 ACR/ARHP Annual Meeting

    Anti-Inflammatory Property Of HDL In NOD1 Ligand Induced Kawasaki Arteritis In Mice

    Hajime Kono1, Tamiko Yanagida2, Kurumi Asako1, Toshihiro Nanki1, Hirotoshi Kikuchi1, Akiko Okamoto1, Akiko Onda3 and Maki Takayama1, 1Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 2Depart ment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan

    Background/Purpose: Atherosclerosis is a chronic metabolic disease of inflammatory processes. Immune cells including monocytes are recruited to the subintimal lesion of the vascular wall and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.